JP2014224108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014224108A5 JP2014224108A5 JP2014089687A JP2014089687A JP2014224108A5 JP 2014224108 A5 JP2014224108 A5 JP 2014224108A5 JP 2014089687 A JP2014089687 A JP 2014089687A JP 2014089687 A JP2014089687 A JP 2014089687A JP 2014224108 A5 JP2014224108 A5 JP 2014224108A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- morpholin
- triazol
- propan
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims 3
- -1 3-Chloro-4-fluorophenyl Chemical group 0.000 claims 2
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 Cerebral infarction Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 206010013663 Drug dependence Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000004384 alopecia Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 201000006474 brain ischemia Diseases 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000000378 calcium silicate Substances 0.000 claims 1
- 229910052918 calcium silicate Inorganic materials 0.000 claims 1
- 235000012241 calcium silicate Nutrition 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 230000001079 digestive Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006180 eating disease Diseases 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003549 soybean oil Substances 0.000 claims 1
- 235000012424 soybean oil Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014089687A JP6387669B2 (ja) | 2013-04-26 | 2014-04-24 | アゾール誘導体を含有する医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013093594 | 2013-04-26 | ||
| JP2013093594 | 2013-04-26 | ||
| JP2014089687A JP6387669B2 (ja) | 2013-04-26 | 2014-04-24 | アゾール誘導体を含有する医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014224108A JP2014224108A (ja) | 2014-12-04 |
| JP2014224108A5 true JP2014224108A5 (fr) | 2017-06-08 |
| JP6387669B2 JP6387669B2 (ja) | 2018-09-12 |
Family
ID=52123088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014089687A Expired - Fee Related JP6387669B2 (ja) | 2013-04-26 | 2014-04-24 | アゾール誘導体を含有する医薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6387669B2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019012567A2 (pt) | 2016-12-22 | 2019-11-26 | Bayer Ag | azolilpirrolonas e azolil-hidantoínas substituídas e sais das mesmas e uso das mesmas como substâncias ativas herbicidas |
| EP3558986A1 (fr) | 2016-12-22 | 2019-10-30 | Bayer CropScience Aktiengesellschaft | 1,2,4-thiadiazolylpyrrolones et 1,2,4-thiadiazolylhydantoïnes substituées et leurs sels et leur utilisation comme agents herbicides |
| WO2020113094A1 (fr) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Composés pyrrole et pyrazole et leurs procédés d'utilisation |
| BR112022017530A2 (pt) * | 2020-03-17 | 2022-10-18 | Sumitomo Pharma Co Ltd | Derivado de oxadiazol |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000063363A (ja) * | 1998-08-12 | 2000-02-29 | Yamanouchi Pharmaceut Co Ltd | 新規なトリアゾール誘導体 |
| US8350043B2 (en) * | 2005-06-07 | 2013-01-08 | Pharmacopeia, Inc. | Azinone and diazinone V3 inhibitors for depression and stress disorders |
| DE102006024024A1 (de) * | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| JP2010229035A (ja) * | 2007-08-01 | 2010-10-14 | Taisho Pharmaceutical Co Ltd | ピリドピリミジン−４−オン誘導体 |
| WO2009130232A1 (fr) * | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Dérivés de pirazolo [1, 5 -a] pyrazine, antagonistes des récepteurs v1b |
| JP5369721B2 (ja) * | 2009-01-30 | 2013-12-18 | 大正製薬株式会社 | ピリドピリミジン−４−オン誘導体 |
| LT2539326T (lt) * | 2010-02-27 | 2017-08-10 | Bayer Intellectual Property Gmbh | Sujungti bisariliniai ariltriazolonai ir jų panaudojimas |
| SG189156A1 (en) * | 2010-10-01 | 2013-05-31 | Taisho Pharmaceutical Co Ltd | 1,2,4-triazolone derivative |
| KR101998442B1 (ko) * | 2011-10-27 | 2019-07-09 | 다이쇼 세이야꾸 가부시끼가이샤 | 아졸 유도체 |
-
2014
- 2014-04-24 JP JP2014089687A patent/JP6387669B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2683355T3 (es) | Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades | |
| JP2011522816A5 (fr) | ||
| JP2015518885A5 (fr) | ||
| JP2017528507A5 (fr) | ||
| JP2018168191A5 (fr) | ||
| JP2009507896A5 (fr) | ||
| JP2014532638A5 (fr) | ||
| JP2014511892A5 (fr) | ||
| NO20073853L (no) | Faste, oralt applikerbare farmasoytiske administreringsformer inneholdende nvaroksaban med modifisert frigivelse | |
| JP2017537940A5 (fr) | ||
| JP2012532874A5 (fr) | ||
| JP2014224108A5 (fr) | ||
| JP2012505836A5 (fr) | ||
| PH12016501651A1 (en) | Triazine compound and use thereof for medical purposes | |
| HRP20171793T1 (hr) | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata | |
| JP2009517411A5 (fr) | ||
| JP2014198723A5 (fr) | ||
| JP2015510916A5 (fr) | ||
| JP2015511609A5 (fr) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2020529995A5 (fr) | ||
| RU2019135261A (ru) | Фармацевтическая композиция, содержащая ингибитор pde9 | |
| PH12014502178A1 (en) | Fused azole derivative | |
| JP2019218379A5 (fr) | ||
| JP2014526508A5 (fr) |